title: [Prevention of superficial bladder cancer with mitomycin C or interferon: final results of a prospective study].
abstract: OBJECTIVE
  Herein we present the final results of a prospective randomized study comparing two prophylactic treatment modalities for superficial bladder tumors: chemotherapy with mitomycin C and immunotherapy with interferon.
  
  
  METHODS
  The study comprised 65 patients. Mitomycin C was utilized in 34 and interferon in 31 patients.
  
  
  RESULTS
  The mitomycin C-treated patients had 41% recurrence, 1.7 recurrence/100 patients-month, 17 months mean time to recurrence and 8.8% tumor progression. The patients receiving interferon had 45% recurrence, 2.4 recurrence/100 patients-month, 12 months mean time to recurrence and 22.2% tumor progression rate. No significant differences were observed between the two groups of patients. Treatment was well-tolerated by both groups and the cost:efficacy ratio was higher for the interferon-treated patients.
  
  
  CONCLUSIONS
  Immunoprophylaxis with interferon is as effective, but costs more than chemoprophylaxis with mitomycin C. Both agents have a moderate effect relative to control of recurrence, time to recurrence and tumor progression.
authors.affiliation: Servicio de Urología, Hospital Xeral de Vigo, Pontevedra, España.
authors.forename: A
authors.initials: A
authors.lastname: Ojea Calvo
authors.forename: F
authors.initials: F
authors.lastname: Domínguez Freire
authors.forename: M
authors.initials: M
authors.lastname: Vérez Vivero
authors.forename: A
authors.initials: A
authors.lastname: Alonso Rodrigo
authors.forename: B
authors.initials: B
authors.lastname: Rodríguez Iglesias
authors.forename: J
authors.initials: J
authors.lastname: Benavente Delgado
authors.forename: M
authors.initials: M
authors.lastname: Barros Rodríguez
authors.forename: Y J
authors.initials: YJ
authors.lastname: Nogueira March
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control*; D011446:Prospective Studies; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016685:Mitomycin
vernacular_title: Profilaxis del cáncer superficial de vejiga con Mitomicina C o Interferón: resultados definitivos de un estudio prospectivo.